Sees FY26 revenue $3.05B-$3.15B, consensus $3.21B. Sees FY26 adjusted EBITDA $720M-$760M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- AMRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Amneal Pharmaceuticals Refinances Term Loans, Lowers Interest Costs
- Amneal Pharmaceuticals added to S&P SmallCap 600 Index
- Amneal Finalizes Nationwide Opioid Settlement Implementation Plan
- Closing Bell Movers: Texas Instruments up 8%, F5 up 11% on earnings